• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Nkarta Inc.

    1/5/26 4:43:55 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $NKTX alert in real time by email
    S-8 1 nktx-20260105.htm S-8 S-8

     

    As filed with the Securities and Exchange Commission on January 5, 2026

    Registration No.333-

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    Nkarta, Inc.

    (Exact name of registrant as specified in its charter)

     

     

    Delaware

     

    47-4515206

    (State or other jurisdiction of

     

    (I.R.S. Employer

    incorporation or organization)

     

    Identification No.)

     

     

     

    Nkarta, Inc.

    1150 Veterans Boulevard

    South San Francisco, CA 94080
    (Address, including zip code, of Principal Executive Offices)

     

     

    Nkarta, Inc. 2020 Performance Incentive Plan

    Nkarta, Inc. Employee Stock Purchase Plan

     

    (Full title of the plan)

     

     

    Paul J. Hastings

    Chief Executive Officer

    Nkarta, Inc.

    1150 Veterans Boulevard

    South San Francisco, CA 94080

    (925) 407-1049

    (Name, address and telephone number, including area code, of agent for service)

     

    COPY TO:

    C. Brophy Christensen, Jr., Esq.

    O’Melveny & Myers LLP

    Two Embarcadero Center, 28th Floor

    San Francisco, California 94111-3823

    (415) 984-8700

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer 

     

    Accelerated filer 

     

     

     

    Non-accelerated filer 

     

    Smaller reporting company 

     

     

     

     

     

    Emerging growth company 

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. 


     

    EXPLANATORY NOTE

    The Registrant is filing this Registration Statement for the purpose of registering additional shares of Common Stock issuable pursuant to the Registrant’s 2020 Performance Incentive Plan and the Registrant’s Employee Stock Purchase Plan and consists only of those items required by General Instruction E to Form S-8.

     

    __________________________

     

    PART I

    INFORMATION REQUIRED IN THE

    SECTION 10(a) PROSPECTUS

    The document(s) containing the information specified in Part I of Form S-8 will be sent or given to participants as specified by Rule 428(b)(1) promulgated under the Securities Act of 1933, as amended (the “Securities Act”).

     


     

    PART II

    INFORMATION REQUIRED IN THE

    REGISTRATION STATEMENT

    Item 3. Incorporation of Certain Documents by Reference

    The following documents of the Company filed with the Securities and Exchange Commission (the “Commission”) are incorporated herein by reference:

    (a) The Company’s Registration Statements on Form S-8, filed with the Commission on August 3, 2020, January 15, 2021, March 17, 2022, January 9, 2023, January 3, 2024 and January 2, 2025 (Commission File Nos. 333-240309, 333-252134, 333-263650, 333-269164, 333-276361, and 333-284111 respectively).

    (b) The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 26, 2025 (Commission File No. 001-39370).

    (c) The portions of the Company’s Definitive Proxy Statement on Schedule 14A, filed with the Commission on April 21, 2025 that are incorporated by reference in Part III of the Company’s Annual Report on Form 10-K for its fiscal year ended December 31, 2024 (Commission File No. 001-39370).

    (d) The Company’s Quarterly Reports on Form 10-Q for the fiscal quarters ended March 31, 2025, June 30, 2025, and September 30, 2025, filed with the Commission on May 14, 2025, August 12, 2025, and November 10, 2025, respectively (each, Commission File No. 001-39370).

    (e) The Company’s Current Reports on Form 8-K, filed with the Commission on March 26, 2025 and June 6, 2025 (each, Commission File No. 001-39370, and in each case only as to the information “filed” with the Commission thereunder for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and not as to information “furnished” thereunder).

    (f) The description of the Company’s Common Stock contained in its Registration Statement on Form 8-A, filed with the Commission on July 2, 2020 as modified by the description of the Company’s Common Stock contained in Exhibit 4.3 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 (each, Commission File No. 001-39370), and any other amendment or report filed for the purpose of updating such description.

    All documents subsequently filed by the Company pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered hereby have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with Commission rules shall not be deemed incorporated by reference into this Registration Statement. Any statement contained herein or in a document, all or a portion of which is incorporated or deemed to be incorporated by reference herein, shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or amended, to constitute a part of this Registration Statement.

    Item 5. Interests of Named Experts and Counsel

    Not applicable.

    2


     

    Item 8. Exhibits

    The exhibits to this Registration Statement are listed below.

     

     

    3


     

    EXHIBIT INDEX

     

     

     

     

     

     

     

    Incorporated by Reference

     

     

    Exhibit

    Number

     

    Description

     

    Form

     

    File No.

     

    Exhibit

     

    Filing Date

     

    Filed

    Herewith

     

     

     

     

     

     

     

     

     

     

    4.1

     

    Nkarta, Inc. 2020 Performance Incentive Plan.

     

    S-1/A

     

    333-239301

     

    10.4

     

    7/2/2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    4.2

     

    Nkarta, Inc. Employee Stock Purchase Plan.

     

    S-1/A

     

    333-239301

     

    10.5

     

    7/2/2020

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    5

     

    Opinion of O’Melveny & Myers LLP.

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.1

     

    Consent of Independent Registered Public Accounting Firm.

     

     

     

     

     

     

     

     

     

    X

     

     

     

     

     

     

     

     

     

     

     

     

     

    23.2

     

    Consent of O’Melveny & Myers LLP (see Exhibit 5).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    24

     

    Power of Attorney (included on signature page thereto).

     

     

     

     

     

     

     

     

     

     

     

    107

     

    Filing Fee Table.

     

     

     

     

     

     

     

     

     

    X

     

    4


     

    SIGNATURES

    Pursuant to the requirements of the Securities Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S8 and has duly caused this Form S-8 Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of South San Francisco, State of California, on January 5, 2026.

     

    NKARTA, INC.

     

     

     

    By:

     

    /s/ Paul J. Hastings

     

     

    Paul J. Hastings

     

     

    Chief Executive Officer

     

     

    POWER OF ATTORNEY

    Each person whose signature appears below constitutes and appoints Paul J. Hastings and Nadir Mahmood, and each of them, acting individually and without the other, as his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him or her and in his or her name, place, and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments, exhibits thereto and other documents in connection therewith) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them individually, or their or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

    5


     

    Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

     

    Signature

     

    Title

     

    Date

     

     

     

     

     

    /s/ Paul J. Hastings

     

    Chief Executive Officer and Director

     

    January 5, 2026

    Paul J. Hastings

     

    (Principal Executive Officer)

     

     

     

     

     

     

     

    /s/ Nadir Mahmood

     

    President

     

    January 5, 2026

    Nadir Mahmood

     

    (Principal Financial and

    Accounting Officer)

     

     

     

     

     

     

     

    /s/ Ali Behbahani

     

    Director

     

    January 5, 2026

    Ali Behbahani, M.D., M.B.A.

     

     

     

     

     

     

     

     

     

    /s/ Michael Dybbs

     

    Director

     

    January 5, 2026

    Michael Dybbs, Ph.D.

     

     

     

     

     

     

     

     

     

    /s/ Simeon George

     

    Director

     

    January 5, 2026

    Simeon George, M.D., M.B.A.

     

     

     

     

     

     

     

     

     

    /s/ Leone Patterson

     

    Director

     

    January 5, 2026

    Leone Patterson, M.B.A.

     

     

     

     

     

     

     

     

     

    /s/ Zachary Scheiner

     

    Director

     

    January 5, 2026

    Zachary Scheiner, Ph.D.

     

     

     

     

     

     

     

     

     

    /s/ Angela Thedinga

     

    Director

     

    January 5, 2026

    Angela Thedinga, M.B.A.

     

     

     

     

     

     

     

     

     

    /s/ George Vratsanos

     

    Director

     

    January 5, 2026

    George Vratsanos, M.D., F.A.C.R.

     

     

     

     

     

     

     

     

     

     

     

    6


    Get the next $NKTX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NKTX

    DatePrice TargetRatingAnalyst
    5/15/2025Outperform → Mkt Perform
    William Blair
    10/9/2024$14.00Buy
    Rodman & Renshaw
    8/14/2024$16.00Outperform → Strong Buy
    Raymond James
    3/22/2024$13.00 → $16.00Strong Buy → Outperform
    Raymond James
    12/22/2022Outperform → Perform
    Oppenheimer
    10/10/2022$25.00Buy
    Canaccord Genuity
    7/28/2022$26.00Buy
    Needham
    7/18/2022$30.00Outperform
    SVB Leerink
    More analyst ratings

    $NKTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Nkarta to Participate in Evercore Healthcare Conference

    SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced its participation in the Evercore 8th Annual Healthcare Conference on Thursday in Miami. Evercore 8th Annual Healthcare ConferenceDecember 4, 202510:50 a.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company advancing the development of allogeneic, off-the-

    12/2/25 7:09:32 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights

    Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in patients receiving only cyclophosphamideEnrollment streamlined across Ntrust-1 and Ntrust-2 under a combined independent Data Safety Monitoring Board (iDSMB) to guide dose escalation Initial data for NKX019 in multiple autoimmune indications expected to be presented at a medical conference in 2026Cash balance of $316.5 million on September 30, 2025, including cash, cash equivalents, and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Ca

    11/10/25 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta to Participate in November Investor Conferences

    SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conferences next month: Stifel 2025 Healthcare ConferenceNovember 12, 202510:40 a.m. ET – fireside chat TD Cowen's Immunology & Inflammation SummitNovember 13, 20255 p.m. ET – fireside chat A simultaneous webcast of the event will be available on the Investors section of Nkarta's website, www.nkartatx.com, and a replay will be archived on the website for approximately 90 days. About NkartaNkarta is a clinical-stage biotechnology company a

    10/30/25 1:14:55 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Ra Capital Management, L.P. bought $30,000,000 worth of shares (3,000,000 units at $10.00) (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    3/29/24 5:38:04 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    George Simeon bought $20,000,000 worth of shares (2,000,000 units at $10.00) (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    3/28/24 4:30:06 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Nkarta downgraded by William Blair

    William Blair downgraded Nkarta from Outperform to Mkt Perform

    5/15/25 8:09:11 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Rodman & Renshaw initiated coverage on Nkarta with a new price target

    Rodman & Renshaw initiated coverage of Nkarta with a rating of Buy and set a new price target of $14.00

    10/9/24 7:55:21 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta upgraded by Raymond James with a new price target

    Raymond James upgraded Nkarta from Outperform to Strong Buy and set a new price target of $16.00

    8/14/24 7:45:34 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    SEC Filings

    View All

    SEC Form S-8 filed by Nkarta Inc.

    S-8 - Nkarta, Inc. (0001787400) (Filer)

    1/5/26 4:43:55 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Nkarta Inc.

    SCHEDULE 13D/A - Nkarta, Inc. (0001787400) (Subject)

    11/24/25 6:48:24 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Nkarta Inc.

    SCHEDULE 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/25 4:05:26 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Officer Rose Shawn Marshall was granted 70,000 shares (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/8/26 5:50:36 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Mahmood Nadir was granted 80,000 shares, increasing direct ownership by 86% to 173,376 units (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/8/26 5:49:10 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Hastings Paul J was granted 94,000 shares, increasing direct ownership by 29% to 416,069 units (SEC Form 4)

    4 - Nkarta, Inc. (0001787400) (Issuer)

    1/8/26 5:48:54 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Financials

    Live finance-specific insights

    View All

    Nkarta Receives FDA Clearance of IND Application for NKX019 in Lupus Nephritis

    New pipeline program builds on academic studies of durable, drug-free remissions in patients with autoimmune disease after CD19-targeted cell therapy NKX019, an allogeneic CAR NK cell therapy targeting CD19+ B cells, could modify refractory autoimmune disease while maintaining NK-driven safety profile Off-the-shelf accessibility and proprietary engineering could eliminate burdens of autologous products and may enable differentiating conditioning regimen Resource prioritization and cost reductions expected to extend cash runway by one year into 2026 to support important clinical data readouts in 2024 Estimated cash and cash equivalents of $278.4 mil

    10/17/23 7:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta to Host Conference Call on Tuesday, October 17 at 8am ET to Discuss Expansion of Clinical Pipeline and Organizational Cost Measures

    SOUTH SAN FRANCISCO, Calif., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that it will host a conference call on Tuesday, October 17, 2023 at 8:00 a.m. ET to discuss clinical program updates and organizational cost measures and resource prioritization to support clinical milestones. Conference Call and WebcastTo access the conference call, please register through this link: https://nkarta-business-update.open-exchange.net/registration A replay will be archived on the Investors section of Nkarta's website, www.nkartatx.com, for approximately four weeks. About NkartaNkart

    10/16/23 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia

    Encouraging antileukemic activity seen with NKX101 in patients with AML, including several with high-risk features, using a modified lymphodepletion incorporating Ara-C (cytarabine)In patients with r/r AML treated with a three-dose regimen of NKX101 at 1.5 billion cells per dose after fludarabine/Ara-C for lymphodepletion, n=6 4 of 6 patients achieved complete response (67% CR/CRi, 50% CR rate)2 CRs with MRD negativity1 patient deepened response to MRD negative CRi with additional cycles NKX101 was well tolerated across dose-levels and lymphodepletion regimensExpansion cohort incorporating Ara-C based lymphodepletion expected to be the basis of NKX101 development moving forwardUpdated clinic

    6/27/23 7:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Nkarta Inc.

    SC 13G - Nkarta, Inc. (0001787400) (Subject)

    12/13/24 5:02:47 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

    SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/24 4:05:12 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Nkarta Inc.

    SC 13G/A - Nkarta, Inc. (0001787400) (Subject)

    11/14/24 8:55:31 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $NKTX
    Leadership Updates

    Live Leadership Updates

    View All

    Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

    SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space. Dr. Rose has dedicated his career to immunology translational medicine and advancing new treatment options for autoimmune patients. In various leadership roles, he has brought

    6/6/25 8:52:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

    Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025

    5/14/25 4:01:00 PM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Nkarta Announces Leadership Updates, Appoints Nadir Mahmood as President

    SOUTH SAN FRANCISCO, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (NASDAQ:NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced changes to its leadership team. Nadir Mahmood, Ph.D., will join Nkarta as President this month, sharing executive leadership responsibilities with Paul J. Hastings, who continues in his role as Chief Executive Officer. Additionally, Nkarta has broadened the role of David R. Shook, M.D., to Chief Medical Officer, Head of Research & Development. Drs. Mahmood and Shook will both report to Mr. Hastings. "This new leadership structure enables Nkarta to meet this transformative moment for cell therapy as

    7/16/24 6:01:00 AM ET
    $NKTX
    Biotechnology: Pharmaceutical Preparations
    Health Care